2024 annual financial data
SAB Biotherapeutics 2024 Operating margin
SAB Biotherapeutics 2024 operating margin with verified reported values.
Direct answer
Operating margin was -3,244.87%.
Operating income was -42,910,520 USD and net income was -34,105,309 USD.
Operating cash flow was -34,292,009 USD.
Get free SAB Biotherapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 1,322,410 USD
- Operating income
- -42,910,520 USD
- Net income
- -34,105,309 USD
- Operating cash flow
- -34,292,009 USD